Switzerland analyzes the impact of Trump's tariffs on the pharmaceutical industry

Switzerland announced on Friday that its ministries are analyzing the potential impact of US tariffs on pharmaceutical products after President Donald Trump announced 100% tariffs on imports of patented drugs starting October 1.

The tariffs will apply to all companies that do not have or are not establishing a production facility in the US.

The Swiss Ministry of Economic Affairs said in a statement that the relevant departments are reviewing the measures in cooperation with the affected sectors of the pharmaceutical industry, even though no details of the planned measures are available yet.

The pharmaceutical sector, which accounts for almost half of Swiss exports and is of strategic importance to the country's economy, could be significantly affected by the new tariffs if manufacturers do not expand their capacities in the US as well.

Major Swiss companies such as Novartis and Roche have already announced investments in US factories to circumvent tariff barriers.

(reuters, sie)